Cosentyx (secukinumab) is a medication used to treat certain types of autoimmune disorders, such as psoriasis and psoriatic arthritis. While there is limited research on the use of Cosentyx during breastfeeding, there are some studies and recommendations available.

According to DrugPatentWatch [1], there are no current patents on Cosentyx that specifically address breastfeeding. However, the medication is known to pass into breast milk, and its effects on infants are unknown. Therefore, the use of Cosentyx during breastfeeding should be carefully considered and discussed with a healthcare provider.

A recent article published in the Journal of Clinical Medicine [2] provides some insight into the use of Cosentyx during pregnancy and breastfeeding. The authors note that while there is limited data on the use of Cosentyx during breastfeeding, it is generally recommended that women avoid breastfeeding while taking the medication. This is because the medication can be passed to the infant through breast milk, and its effects on the infant are unknown.

Similarly, Drugs.com [3] advises that Cosentyx should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. The medication should also be used with caution during breastfeeding, and women should be advised to either discontinue the medication or stop breastfeeding.

In conclusion, while there is limited research on the use of Cosentyx during breastfeeding, it is generally recommended that women avoid breastfeeding while taking the medication. This is because the medication can be passed to the infant through breast milk, and its effects on the infant are unknown. Women who are considering taking Cosentyx during breastfeeding should discuss the potential risks and benefits with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/
[3] https://www.drugs.com/pregnancy/secukinumab.html